Review of Effectiveness of Live Attenuated Influenza Vaccine

Lisa Grohskopf, MD, MPH

Influenza Division, CDC

Advisory Committee on Immunization Practices

February 21, 2018

Outline

- Background
- Combined individual patient-level analysis of LAIV effectiveness
  - U.S. data
- Systematic review and meta analysis of published literature on LAIV effectiveness
  - U.S. and non-U.S. data
- Work Group considerations
- Proposed recommendation

Background

LAIV Recommendations Summary, 2003-2016

- 2003: LAIV3 licensed for 5 through 49 years; in 2007, for 2 through 49 years
  - Recommended for healthy non-pregnant persons; no preference
- 2012: LAIV4 licensed; replaced LAIV3 for 2013-14 season
  - Recommended for healthy non-pregnant persons; no preference
- 2014: Preferential recommendation for healthy 2- through 8-year olds
  - Basis: pre-2009 pandemic data showing superiority of LAIV3 to IIV
- February 2015: Preferential recommendation removed following poor effectiveness of LAIV4 against H1N1pdm09 among 2- through 17-year-olds during 2013-14 season
  - No statistically significant effectiveness, whereas IIV was effective

LAIV Recommendations Summary, 2003-2016 (cont'd)

- June 2015: No better performance than IIV against H3N2 in 2014-15
  - Poor VE for LAIV4 and IIV during a drifted H3N2-predominant season
  - LAIV3 superior to IIV for drifted H3N2 viruses in pre-pandemic study
- 2015-16 season: LAIV4 H1N1pdm09-like virus changed to A/Bolivia/559/2013/H1N1pdm09 for 2015-16
  - Studies revealed poor fitness of previous LAIV4 H1N1pdm09-like vaccine virus, A/California/7/2009/H1N1pdm09
- June 2016: Poor effectiveness of LAIV4 against H1N1pdm09 for 2015-16
  - LAIV4 not recommended in the United States for 2016-17 and 2017-18

U.S. Flu VE Network

2015-16 U.S. Season

Presented at ACIP, June 2016

ICICLE: 2015-16 Adjusted Estimates of Effectiveness

MedImmune ICICLE Study

2015-16 U.S. Season

Presented at ACIP, June 2016

Variability in LAIV Effectiveness Estimates—Observations From Data Presented in June, 2016

- Primary concern: effectiveness against H1N1pdm09 in 2013-14, 2015-16
- Point estimates of LAIV4 effectiveness against H1N1pdm09 varied in U.S.
- Higher point estimates in studies conducted outside the U.S.
  - e.g., Canada, United Kingdom, Germany, Finland (which have continued to use LAIV)
- Sources of variability not completely understood; possibilities include
  - Differences in use of trivalent as compared with quadrivalent LAIV
  - Small sample size and imprecision of estimates in most individual studies
    - Particularly when stratifying by vaccine types and influenza types/subtypes
  - Differences in prevalence of prior vaccination among children in different countries and populations

Review of LAIV Effectiveness data, 2010-11 through 2016-17

- Combined individual patient-level analysis of U.S. studies (US-IPD)
  - 5 studies and three seasons with LAIV4 (2013-14 through 2015-16)
  - Greater power for age group analyses
  - More precise estimates through pooling of data across multiple studies
  - Evaluation of effect of prior vaccination
- Systematic review and meta-analysis (SR/MA)
  - U.S. and non-U.S. studies from 2010-11 season forward
  - Evaluation of quality of individual studies (risk of bias; problems related to small sample size)
  - Summary VE results and exploration of heterogeneity

Combined US Individual Patient Level Analysis (US-IDP)

Individual patient-level data meta-analysis of LAIV and IIV effectiveness among US children aged 2–17 years, 2013–14 through 2015–16 influenza seasons

Jessie Chung, MPH

Brendan Flannery PhD

Included studies summary—Combined US-IPD analysis

Study	N	Study Inclusion	Testing	Current Season vaccination status
Influenza Clinical Investigation in Children (ICICLE), MedImmune	3521	ARI with fever <5 days duration	RT-PCR	EMR, immunization registries
Influenza Incidence Surveillance Project (IISP), CDC	1102	ARI with fever and cough/sore throat ≤7 days duration	RT-PCR	EMR, immunization registries
LSU Health Sciences Center (LSU)	3822	Clinical laboratory testing for influenza	Rapid test; RVP of negatives	Immunization registry
US Air Force School of Aerospace Medicine dependents (USAFSAM), US DoD	1935	ARI with fever and cough/sore throat <72 hours duration	Culture, RT-PCR	Immunization registry, parent report
Flu VE Network, CDC	6793	ARI with cough ≤7 days duration	RT-PCR	EMR, immunization registries

Adjusted VE of LAIV4 by influenza (sub)type and age group—Combined US-IPD analysis

Relative Effectiveness Slides—Example of Format

Any influenza
(all 3 seasons)

A/H1N1pdm09
(2013-14 and
2015-16)

Influenza (sub)type/ Age group	Total	Influenza Positive N Vaccinated (%)	Influenza Negative N Vaccinated (%)	aOR (95% CI)	
Influenza A and B					
2-17 y					
LAIV	1979	476 (24)	1503 (76)	1.48 (1.28 ,1.7)	
IIV	4579	727 (16)	3852 (84)		
2-4 y					
LAIV	625	121 (19)	504 (81)	2 (1.5 ,2.67)	
IIV	1950	199 (10)	1751 (90)		
5-8 y					
LAIV	727	196 (27)	531 (73)	1.39 (1.11 ,1.74)	
IIV	1216	252 (21)	964 (79)		
9-17 y					
LAIV	627	159 (25)	468 (75)	1.19 (0.92 ,1.56)	
IIV	1413	276 (20)	1137 (81)		
A/H1N1pdm09					
2-17 y					
LAIV	868	140 (16)	728 (84)	2.66 (2.06 ,3.44)	
IIV	2397	156 (7)	2241 (94)		
2-4 y					
LAIV	283	43 (15)	240 (85)	3.12 (1.62 ,6.01)	
IIV	1057	61 (6)	996 (94)		
5-8 y					
LAIV	331	67 (20)	264 (80)	2.79 (2.09 ,3.71)	
IIV	621	56 (9)	565 (68)		
9-17 y					
LAIV	254	30 (12)	224 (88)	2.19 (1.26 ,3.81)	
IIV	719	39 (5)	680 (95)		

0.10   1.0   10.0
Adjusted Odds Ratio
<---Favors LAIV   Favors IIV--->

A/H3N2

(2014-15)

Any Influenza B

(all 3 seasons)

Influenza (sub)type/ Age group	Total	Influenza Positive N Vaccinated (%)	Influenza Negative N Vaccinated (%)	aOR (95% CI)
Influenza A/H3N2 2-17 y				
LAIV	1009	234 (23)	775 (77)	1.3 (1.06 ,1.58)
IIV	1922	311 (16)	1611 (84)	
2-4 y				
LAIV	320	56 (18)	264 (83)	1.99 (1.49 ,2.64)
IIV	822	67 (8)	755 (92)	
5-8 y				
LAIV	353	86 (24)	267 (76)	1.16 (0.74 ,1.82)
IIV	506	107 (21)	399 (79)	
9-17 y				
LAIV	336	92 (27)	244 (73)	1.15 (0.87 ,1.51)
IIV	594	137 (23)	457 (77)	
Influenza B 2-17 y				
LAIV	1561	58 (4)	1503 (96)	0.72 (0.46 ,1.13)
IIV	4049	197 (5)	3852 (95)	
2-4 y				
LAIV	511	7 (1)	504 (99)	0.56 (0.21 ,1.53)
IIV	1798	47 (3)	1751 (97)	
5-8 y				
LAIV	556	25 (5)	531 (96)	0.68 (0.42 ,1.11)
IIV	1039	75 (7)	964 (93)	
9-17 y				
LAIV	494	26 (5)	468 (95)	0.81 (0.38 ,1.72)
IIV	1212	75 (6)	1137 (94)	

0.10   1.0   10.0
Adjusted Odds Ratio
<---Favors LAIV   Favors IIV--->

Contributors

ICICLE: Herve Caspard, Christopher Ambrose, Katherine Poehling, Timothy Peters, Edward Belongia, Blaise Congeni, Manjusha Gaglani, Marie Griffin, Stephanie Irving, Poornima Kavathekar, Huong McLean, Allison Naleway, Kathleen Ryan, H Keipp Talbot

IISP: Ashley Fowlkes, Andrea Steffens, Heather Rubino, Janet Hamilton, Karen Martin, Ruth Lynfield, Jill Baber, Michelle Feist, Steve Di Lonardo, Lisa McHugh, Jonathan Temte, Maureen Landsverk

LSU: Rodolfo Begue

USAFSAM: Susan Federinko, Laurie DeMarcus

USFLUVE: Brendan Flannery, Alicia Fry, Arnold Monto, Emily Martin, Edward Belongia, Huong McLean, Manjusha Gaglani, Michael Jackson, Lisa Jackson, Richard Zimmerman, Mary Patricia Nowalk

Systematic Review and Meta-analysis (SR/MA)

Systematic Review and Meta-analysis of Studies Reporting LAIV Effectiveness, 2010-11 through 2016-17

Jill Ferdinands   Lisa Grohskopf

Leslie Sokolow   Jessie Chung

Brendan Flannery   Ivo Foppa

February 21, 2018

Search Strategy

- MEDLINE, EMBASE, CINAHL, Scopus, ClinicalTrials.gov, Cochrane Register of Controlled Trials; indexed January 1, 2011-October 31, 2017

- English language

- 2010-11 through 2016-17 seasons

- Key terms:
  - influenza, influenza vaccine (or vaccination, shot, injection, spray, inoculation, mist), live attenuated influenza vaccine, LAIV, cold adapted influenza vaccine, CAIV, FluMist, case-control study, vaccine efficacy, vaccine effectiveness, relative vaccine efficacy, relative vaccine effectiveness

- Reference lists of reviewed to identify additional published studies.

- Titles/abstracts screened by ≥2 reviewers.

- Articles reviewed by ≥2 reviewers.

Study Inclusion Criteria

- Study designs:
  - Randomized controlled trials
  - Observational studies:
    - Test-negative case-control
    - Cohort
- Study population: Children 2 through 17 years of age
- Intervention: ≥1 dose of LAIV, administered intranasally
- Comparators: Unvaccinated, placebo, non-influenza vaccine, or intramuscular inactivated influenza vaccine
- Outcomes: Laboratory-confirmed (by PCR and/or culture) influenza outcomes (e.g., medically-attended outpatient influenza infection, influenza-associated hospitalizations)

Study Quality Assessment

- Randomized studies
  - Cochrane Risk of Bias Tool
- Observational Studies
  - ROBINS-I (Risk of Bias in Non-randomized Studies of Interventions; Cochrane Collaboration, Sterne JAC et al, BMJ 2016;355:i4919)
  - Sparse Data Bias (Adapted from Greenland S, et al, BMJ. 2016 Apr 27;352:i1981)

Literature Search Results

Two search periods

- January 2011—November 2016
- November 2016—October 2017

Total = 1136

Duplicate articles = 37

Predated 2010-11 season = 105

Not influenza = 297

Non-human = 11

Influenza but unrelated to vaccines = 82

Influenza vaccines but unrelated to VE = 484

VE but unrelated to LAIV = 29

LAIV VE but unsuitable* = 71

Non-English = 2

Suitable = 18

* VE reviews and meta-analyses; Analyses using same population as other abstracted studies; Interim and mid-season VE estimates; Outcome not of interest; Methodological issues; Participants outside age range of interest, Non-US LAIV products; Protocol descriptions and ClinicalTrials.gov entries with no published data

Included Paper Characteristics

- 15 test-negative case-control studies (TNCC)
  - United States (9), United Kingdom (3), Canada (2), Germany (1)
- 1 prospective cohort study
  - United States (1)
- 2 cluster randomized trials
  - Canada (2)
- No individually randomized trials
- One retrospective cohort study from Finland did not meet testing modality criteria
  - included in sensitivity analysis for pooled H1N1pdm09 estimate

Study Quality—Observational Studies

- ROBINS-I (16 papers)
  - Low risk   0
  - Moderate risk   13
  - Serious risk   3 → Lack of adjustment for a potential confounding variable of interest
  - Critical Risk   0
- Sparse data bias (45 estimates, LAIV vs. unvaccinated, 2-17 years)
  - Low risk   16
  - Moderate risk   2
  - Serious risk   21 → Most commonly because events per variable (EPV) <10 (i.e., model adjusted for too many variables relative to number of influenza cases)
  - Undetermined   6

Odds of influenza A or B virus infection among children receiving LAIV compared to unvaccinated children, age 2-17 yr, by precision (n=15)

Pooled VE
LAIV vs. unvaccinated:
45% (32 to 56)

Source	OR (95% CI)
Zimmerman 2016 (2014-15)	0.88 [0.68; 1.14]
McLean 2015 (2012-13)	0.51 [0.36; 0.72]
McLean 2017 (2014-15)	0.50 [0.34; 0.73]
Jackson 2017 (2015-16)	0.95 [0.61; 1.47]
Gaglani 2016 (2013-14)	0.98 [0.63; 1.53]
Caspard 2016 (2013-14)	0.68 [0.41; 1.13]
Poehling 2017 (2015-16)	0.54 [0.31; 0.94]
Pebody 2016 (2015-16)	0.42 [0.24; 0.75]
Chung 2017 (2010-11)	0.43 [0.24; 0.76]
Ohmit 2014 * (2011-12)	0.44 [0.25; 0.79]
Pebody 2015 * (2014-15)	0.62 [0.35; 1.10]
Pebody 2017 (2016-17)	0.34 [0.17; 0.70]
Skowronski 2017 * (2015-16)	0.26 [0.10; 0.65]
Helmeke 2015 (2012-13)	0.16 [0.05; 0.53]
Skowronski 2015 * (2013-14)	0.17 [0.04; 0.75]
	0.55 [0.44; 0.68]

More precise

Less precise

Heterogeneity: χ^2_{14} = 36.18 (P < .01), I^2 = 61%

Odds Ratio

Ordered by precision

*Crude estimate

Odds of influenza A(H1N1)pdm09 virus infection among children receiving LAIV compared to unvaccinated children, age 2-17 yr, by precision (n=10)

Pooled VE
LAIV vs.
unvaccinated
25% (6 to 40)

Source — **OR (95% CI)**

Source	OR (95% CI)
Caspard 2016 (2013-14)	0.87 [0.59; 1.27]
Gaglani 2016 (2013-14)	0.88 [0.52; 1.48]
Jackson 2017 (2015-16)	1.19 [0.67; 2.12]
Pebody 2016 (2015-16)	0.58 [0.32; 1.09]
Poehling 2017 (2015-16)	0.50 [0.25; 1.01]
Chung 2017 (2010-11)	0.85 [0.35; 2.08]
Skowronski 2017 * (2015-16)	0.49 [0.17; 1.37]
Ohmit 2016 * (2013-14)	0.23 [0.05; 1.04]
Helmeke 2015 (2012-13)	0.61 [0.13; 2.81]
Skowronski 2015 * (2013-14)	0.14 [0.02; 1.10]
	0.75 [0.60; 0.94]

More precise

Less precise

Heterogeneity: χ^2_9 = 10.96 (P = .28), I^2 = 18%

Odds Ratio

0.05   0.5   1   2

Ordered by descending precision of estimate
*Crude estimate

27

Odds of influenza A(H1N1)pdm09 virus infection among children receiving LAIV compared to unvaccinated children, age 2-17 yr, by location (n=10)

Pooled VE
LAIV vs. unvaccinated
US: 17% (-6 to 35)
Non-US: 48% (15 to 68)

Source	OR (95% CI)
US	
Chung 2017 (2010-11)	0.85 [0.35; 2.08]
Caspard 2016 (2013-14)	0.87 [0.59; 1.27]
Gaglani 2016 (2013-14)	0.88 [0.52; 1.48]
Ohmit 2016 (2013-14)	0.23 [0.05; 1.04]
Jackson 2017 (2015-16)	1.19 [0.67; 2.12]
Poehling 2017 (2015-16)	0.50 [0.25; 1.01]
Pooled OR	0.83 [0.65; 1.06]

Heterogeneity: $\chi_5^2 = 6.36$ ($P = .27$), $I^2 = 21\%$

Source	OR (95% CI)
Non-US	
Helmeke 2015 (2012-13)	0.61 [0.13; 2.81]
Skowronski 2015 (2013-14)	0.14 [0.02; 1.10]
Pebody 2016 (2015-16)	0.58 [0.32; 1.09]
Skowronski 2017 (2015-16)	0.49 [0.17; 1.37]
Pooled OR	0.52 [0.32; 0.85]

Heterogeneity: $\chi_3^2 = 1.73$ ($P = .63$), $I^2 = 0\%$

0.75 [0.60; 0.94]

Heterogeneity: $\chi_9^2 = 10.96$ ($P = .28$), $I^2 = 18\%$

*Crude estimate

0.05   0.5   1   2

Odds Ratio

Odds of influenza A(H1N1)pdm09 virus infection among children receiving LAIV compared to unvaccinated children, age 2-17 yr, by LAIV formulation (n=10)

Pooled VE:
LAIV vs. unvaccinated
LAIV4:   24% (2 to 41)
LAIV3:   38% (-32 to 71)

Source	OR (95% CI)
Quadrivalent	
Caspard 2016 (2013-14)	0.87 [0.59; 1.27]
Gaglani 2016 (2013-14)	0.88 [0.52; 1.48]
Ohmit 2016 (2013-14)	0.23 [0.05; 1.04]
Jackson 2017 (2015-16)	1.19 [0.67; 2.12]
Pebody 2016 (2015-16)	0.58 [0.32; 1.09]
Poehling 2017 (2015-16)	0.50 [0.25; 1.01]
Skowronski 2017 (2015-16)	0.49 [0.17; 1.37]
Pooled OR	0.76 [0.59; 0.98]
Heterogeneity: $\chi^2_6 = 8.24$ ($P = .22$), $I^2 = 27\%$	
Trivalent	
Chung 2017 (2010-11)	0.85 [0.35; 2.08]
Helmeke 2015 (2012-13)	0.61 [0.13; 2.81]
Skowronski 2015 (2013-14)	0.14 [0.02; 1.10]
Pooled OR	0.62 [0.29; 1.32]
Heterogeneity: $\chi^2_2 = 2.45$ ($P = .29$), $I^2 = 18\%$	
	0.75 [0.60; 0.94]

Heterogeneity: $\chi^2_9 = 10.96$ ($P = .28$), $I^2 = 18\%$

*Crude estimate

Sensitivity Analysis: Inclusion of *Nohynek 2016* influenza A estimate†
Odds of influenza A(H1N1)pdm09 virus infection among children receiving LAIV compared to unvaccinated children, age 2-17 yr


Without Nohynek 2016

Source	OR (95% CI)
Chung 2017 (2010-11)	0.85 [0.35; 2.08]
Helmeke 2015 (2012-13)	0.61 [0.13; 2.81]
Caspard 2016 (2013-14)	0.87 [0.59; 1.27]
Gaglani 2016 (2013-14)	0.88 [0.52; 1.48]
Skowronski 2015 * (2013-14)	0.14 [0.02; 1.10]
Ohmit 2016 * (2013-14)	0.23 [0.05; 1.04]
Jackson 2017 (2015-16)	1.19 [0.67; 2.12]
Pebody 2016 (2015-16)	0.58 [0.32; 1.09]
Poehling 2017 (2015-16)	0.50 [0.25; 1.01]
Skowronski 2017 * (2015-16)	0.49 [0.17; 1.37]
	0.75 [0.60; 0.94]

Heterogeneity: $\chi^2_9 = 10.96$ ($P = .28$), $I^2 = 18\%$

Ordered by season
*Crude estimate

With Nohynek 2016

Source	OR (95% CI)
Chung 2017 (2010-11)	0.85 [0.35; 2.08]
Helmeke 2015 (2012-13)	0.61 [0.13; 2.81]
Caspard 2016 (2013-14)	0.87 [0.59; 1.27]
Gaglani 2016 (2013-14)	0.88 [0.52; 1.48]
Skowronski 2015 * (2013-14)	0.14 [0.02; 1.10]
Ohmit 2016 * (2013-14)	0.23 [0.05; 1.04]
Jackson 2017 (2015-16)	1.19 [0.67; 2.12]
Pebody 2016 (2015-16)	0.58 [0.32; 1.09]
Poehling 2017 (2015-16)	0.50 [0.25; 1.01]
Skowronski 2017 * (2015-16)	0.49 [0.17; 1.37]
Nohynek 2016 (2015-16)	0.52 [0.35; 0.78]
	0.69 [0.54; 0.87]

Heterogeneity: $\chi^2_{10} = 13.51$ ($P = .20$), $I^2 = 26\%$

Ordered by season
*Crude estimate

Pooled VE excluding *Nohynek et al*
LAIV vs. unvaccinated:
25% (6 to 40)

Pooled VE including *Nohynek et al*
LAIV vs. unvaccinated:
31% (13 to 46)

†Estimate for Influenza A, presumed predominantly H1N1pdm09; study population includes only 2-year-olds

Odds of influenza A(H1N1)pdm09 virus infection among children receiving LAIV compared to children receiving IIV (relative effectiveness), age 2-17 yr (n=4)

Source	OR (95% CI)
Chung 2017 (2010-11) n = 522	5.53 [1.35; 22.71]
Chung 2017 (2013-14) n = 613	2.65 [1.34; 5.26]
Poehling 2017 (2015-16) n = 389	1.71 [0.78; 3.74]
Skowronski 2017 * (2015-16) n = 47	3.75 [0.65; 21.74]
	2.52 [1.58; 4.02]

Heterogeneity: $\chi_3^2 = 2.35$ ($P = .50$), $I^2 = 0\%$

Odds Ratio

←——— Favors LAIV   Favors IIV ———→

Ordered by season
*Crude estimate

Odds of influenza B virus infection among children receiving LAIV compared to children receiving IIV (relative effectiveness), age 2-17 yr (n=5)


Source — OR (95% CI)

Chung 2017 (2010-11), n = 548 — 0.46 [0.15; 1.41]
Chung 2017 (2012-13), n = 694 — 0.93 [0.55; 1.57]
McLean 2017 (2014-15), n = NA — 0.18 [0.06; 0.54]
Poehling 2017 (2015-16), n = 380 — 1.20 [0.51; 2.84]
Skowronski 2017 * (2015-16), n = 53 — 0.27 [0.05; 1.40]

0.55 [0.27; 1.12]

Heterogeneity: $\chi^2_4 = 10.22$ ($P = .04$), $I^2 = 61\%$

Odds Ratio: 0.05   0.5   1   2   5

← Favors LAIV   Favors IIV →

Ordered by season
*Crude estimate

Odds of influenza A(H3N2) virus infection among children receiving LAIV compared to children receiving IIV (relative effectiveness), age 2-17 yr (n=4)

Source	OR (95% CI)
Chung 2017 (2010-11), n = 534	1.89 [0.68; 5.24]
Chung 2017 (2011-12), n = 640	0.73 [0.30; 1.77]
Chung 2017 (2012-13), n = 694	0.77 [0.44; 1.33]
Mclean 2017 (2014-15), n = NA	1.17 [0.73; 1.87]
	1.01 [0.73; 1.38]

Heterogeneity: $\chi_3^2 = 3.28$ ($P = .35$), $I^2 = 9\%$

Odds Ratio scale: 0.05 0.2 0.5 1 2 5 8

⟵ Favors LAIV   Favors IIV ⟶

Ordered by season

Summary points—US-IPD and SR/MA

- LAIV vs. no vaccine for influenza A(H1N1)pdm09:
  - Significant effectiveness for 9-17 yrs in US-IPD
  - In SR/MA, significant effectiveness only in non-US studies
    - More imprecise estimates/higher risk of bias for 3/4 of these
  - No studies with effectiveness estimates for LAIV containing A/Slovenia
- LAIV vs. IIV for influenza A(H1N1)pdm09:
  - IIV better for all age groups in US-IPD
  - IIV better in SR/MA
- LAIV vs. IIV for influenza B: Point estimate favors LAIV for both analyses, but not significantly different
- LAIV vs. IIV for A(H3N2): IIV better for 2-4 yrs in US-IPD; no significant difference in other age groups or in SR/MA

Limitations

- For these analyses:
  - B lineages not analyzed separately
- LAIV4 is compared against a variety of different products (all IIVs)
  - In general do not know relative proportions of IIV3 and IIV4
  - Many different IIV formulations

In general:
- No US VE data available for LAIV4 since 2015-16
- VE for current LAIV4 formulation against H1N1pdm09 unknown

What is new since 2016? What is still not known?

- LAIV4 contains new H1N1pdm09-like virus (A/Slovenia) since 2017-18 (used in UK, Finland, Canada)
  - H3N2-predominant season thus far; no H1N1pdm09 VE estimates
- Recent shedding/immunogenicity data for new H1N1pdm09-like virus encouraging
  - Effectiveness of this formulation against H1N1pdm9 not known
  - Likely to remain unknown until next H1N1-predominant season (assuming adequate uptake)
  - Cannot predict when this will occur

Variability in VE estimates

- VE varies with many factors e.g.:
  - Host factors (age, health status)
  - Influenza type/subtype
  - Different seasons

- Many influenza vaccines licensed in the US (13, including LAIV)
  - Estimates of effectiveness of individual products may vary even within a given vaccine category (e.g., among different IIVs)
  - However, in many instances comparative data for different individual products are not available
  - Recommendations for other individual influenza vaccines not generally based upon comparative effectiveness data
    - Given other sources of variability in VE, might not be possible to demonstrate differences in all populations

Conclusions

- Since 2013-14, a plausible root cause of poor effectiveness of LAIV4 against H1N1pdm09 identified

- Encouraging shedding and immunogenicity evidence that problem may be addressed with new H1N1pdm09 virus
  - Caveat: whether this problem is solved will not be known until there is an effectiveness estimate against H1N1pdm09

- New LAIV vaccine virus selection processes to be applied going forward

- Combined analyses indicate LAIV4 effective compared with no vaccination against all influenza and influenza B among 2-17 year olds
  - IIV better vs. H1N1pdm09; against all influenza in some age groups
  - No clear difference in performance of LAIV vs. IIV for H3N2
  - Decision to recommend (or not) individual influenza vaccines not generally based upon effectiveness comparisons to other products

Problem, Benefits/Harms, Values, Acceptability, and Implementation

Acknowledgments

Influenza Division

Noreen Alabi

Lenee Blanton

Lynnette Brammer

Joe Bresee

Alicia Budd

Jessie Chung

Jill Ferdinands

Brendan Flannery

Alicia Fry

Dan Jernigan

Jackie Katz

Krista Kniss

Natalie Kramer

Desiree Mustaquim

Sonja Olsen

Leslie Sokolow

Calli Taylor

Jerry Tokars

Tim Uyeki

Immunization Safety Office

Karen Broder

Frank Destefano

Penina Haber

Tom Shimabukuro

Immunization Services Division

Carla Black

Carolyn Bridges

Sam Graitcer

Andrew Kroger

Amy Parker Fiebelkorn

Tammy Santibanez

Jeanne Santoli

Jim Singleton

Yusheng Zhai

Problem:

- Influenza is an important cause of morbidity and mortality in children.
  - Pediatric deaths ranging from 37 (2011-12) to 171 (2012-13) each non-pandemic season since 2004-05;
  - 358 deaths during 2009 pandemic period.
  - Also important cause of hospitalizations—data from *FluView Interactive:*

	Hospitalizations/100,000 persons-years	
Season	0-4 years	5-17 years
2013-14	47.3	9.4
2014-15	57.3	16.6
2015-16	42.5	9.7
2016-17	40.8	15.5

Benefits vs. Harms:

- Benefit of the current formulation of LAIV4 against H1N1pdm09-like viruses is currently not known (no effectiveness data yet)

- Data suggest good effectiveness of LAIV4 against influenza B viruses

- Data suggest LAIV4 is comparable to IIV against H3N2

- No new safety concerns raised for LAIV4 at the time that the recommendation for its use was removed

- Potential for harm if new formulation of LAIV4 is not effective

Values: How does the target population view the balance of the benefits and risks?

- Some communications (published/unpublished letters) have expressed concern that lack of recommendation for LAIV may be detrimental in some settings (e.g., school-based clinics)

- Maintaining consumer confidence in influenza vaccines is important in the setting of low VE estimates overall

Acceptability: Risk of recommending LAIV without effectiveness data against H1N1 with the new strain

Work Group Perspectives: A plausible root cause of reduced effectiveness against H1N1pdm09 identified

- Some expressed view other factors (interference) may have contributed
- Varying viewpoints regarding promise of the shedding study data
  - Some viewed it as encouraging.
  - Others expressed concern about the size of the study and problems with using immunogenicity/shedding to gauge effectiveness of LAIV
- If issue not resolved, potentially more influenza cases.
- Understanding that influenza VE varies by season for all vaccines, and that initial licensure of some newer vaccines (e.g., some recent quadrivalents) has been based upon immunogenicity data
  - Risk similar to introduction of new influenza vaccine product

Acceptability: Risk that if LAIV is not recommended in the US during 2018-2019, it may not return to market

Work Group Perspectives: It is valued to have multiple types of influenza vaccine available

- LAIV remains a licensed product.
- Challenge of holding all manufacturers to the same standards for effectiveness of influenza vaccines
  - Effectiveness of LAIV has been examined each season
  - For most other individual influenza vaccines, recommendation is not based upon annual assessment of product-specific VE

Implementation: Has influenza vaccine coverage been impacted by not recommending LAIV?

- National vaccination coverage remained stable during the 2016-2017 influenza season
  - Local variation likely, reports of reduced coverage in areas with strong school-based programs that relied on LAIV

- National coverage did not increase, and was 2% lower in the 5-12 year-old age group

Influenza Vaccination Coverage by Age Group, Children 6 months–17 years, NIS-Flu, United States, 2016–17 Season

Age Group	Unweighted Sample Size	%* ±95% CI†	Difference from the 2015−16 Season ±95% CI
6 months–17 years	143,169	59.0 ± 0.7	-0.3 ± 1.1
6 months–4 years	44,094	70.0 ± 1.3	0.0 ± 1.9
6–23 months	16,374	76.3 ± 2.0	1.0 ± 2.6
2–4 years	27,720	66.2 ± 1.6	-0.6 ± 2.4
5–17 years	99,075	55.6 ± 0.8	-0.3 ± 1.2
5–12 years	63,130	59.9 ± 1.0	-1.9 ± 1.6‡
13–17 years‡	35,945	48.8 ± 1.3	2.0 ± 1.9‡

*Percentage vaccinated.
† Confidence interval half-widths.
‡ Statistically significant difference between the 2016–17 season and the 2015–16 season by t-test (P<0.05).

Policy Question: Should LAIV be recommended for the 2018-19 season?

Factor	WG Interpretation
Problem	• Influenza is an important source of morbidity and mortality among children.
Benefits and harms	• Benefit of LAIV for H3N2 comparable to IIV. • Data suggest good effectiveness for influenza B compared with no vaccine. • Limited immunogenicity and shedding data suggest new H1N1pdm09 virus in LAIV4 may promote improved effectiveness (however, this is not yet known). • No vaccine safety concerns at the time LAIV vaccine was not recommended by ACIP. • Potential for harm if vaccine ineffective.
Values	• Several papers and unpublished and published letters, indicate support for availability of a non-injectable formulation of influenza vaccine.
Acceptability	• Varying levels of accepting risk of vaccine not being as effective against H1N1 and potential detriment to confidence in influenza vaccines.
Implementation	• While national coverage appears not to have been impacted by lack of LAIV recommendation, LAIV is an important option for school-based clinics and may contribute to efforts to increase vaccination coverage.
Summary	• There was not complete agreement on the WG. • Most felt the issue should be discussed at ACIP. • A recommendation would need to acknowledge lack of effectiveness data for current LAIV4 against H1N1pdm09 like viruses.